160893-68-5

Upstream product

• 99-06-9 3-Carboxyphenol 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 106-96-7 propargyl bromide 

Downstream Products

• 19438-10-9 methyl 3-hydroxybenzoate 
• 85607-73-4 3-(prop-2-yn-1-yloxy)benzoic acid 
• 1192759-01-5 C₄₁H₅₇N₈O₁₅P 
• 175014-35-4 C₂₃H₂₆N₂O₃ 
• 1261963-83-0 C₂₃H₂₈N₂O₃ 
• 1261963-84-1 C₂₁H₂₁ClN₂O₃ 
• 1261963-86-3 C₂₁H₂₁ClN₂O₃ 
• 1261963-88-5 C₂₁H₂₁ClN₂O₃ 
• 1261963-89-6 C₂₁H₂₀Cl₂N₂O₃ 
• 1261963-90-9 C₂₁H₂₀N₄O₇ 
• 1261963-93-2 C₂₃H₂₆N₂O₃ 
• 1261963-94-3 C₂₃H₂₈N₂O₃ 
• 1261963-92-1 C₂₃H₃₄N₂O₃ 
• 71641-10-6 2-methylbenzofuran-4-carboxylic acid 

Relevant academic research and scientific papers

Metal-Free Catalyzed Cyclization of N-Methoxybenzamides to Construct Quaternary Carbon-Containing Isoindolinones

Through the intramolecular cyclization of N-methoxybenzamides, a simple and efficient method for constructing valuable isoindolinones under metal-free conditions was developed. The reaction was featured by employing low-cost catalyst, simple operation, 100% atomic economy and excellent regioselectivity. Moreover, a detailed computational study on the reaction system has been performed to clarify the mechanism. This protocol tolerated a variety of functional groups and provided a metal-free protocol for the synthesis of chromane- or tetrahydroquinoline-fused isoindolinones in good yields.

BIFUNCTION CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE

The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor.

AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES

2-Acylindazole compounds of formula I or formula II are disclosed. These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.

Natural-Product-Inspired Aminoepoxybenzoquinones Kill Members of the Gram-Negative Pathogen Salmonella by Attenuating Cellular Stress Response

Gram-negative bacteria represent a challenging task for antibacterial drug discovery owing to their impermeable cell membrane and restricted uptake of small molecules. We herein describe the synthesis of natural-product-derived epoxycyclohexenones and explore their antibiotic activity against several pathogenic bacteria. A compound with activity against Salmonella Typhimurium was identified, and the target enzymes were unraveled by quantitative chemical proteomics. Importantly, two protein hits were linked to bacterial stress response, and corresponding assays revealed an elevated susceptibility to reactive oxygen species upon compound treatment. The consolidated inhibition of these targets provides a rationale for antibacterial activity and highlights epoxycyclohexenones as natural product scaffolds with suitable properties for killing Gram-negative Salmonella.

BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

One-pot esterification-click (CuAAC) and esterification-acetylene coupling (Glaser/Eglinton) for functionalization of Wang polystyrene resin

We report three new sets of one-pot reactions for functionalization of Wang polystyrene resin and its derivatives. We first show that it is possible to combine esterification and CuAAC (Copper-Catalyzed Alkyne-Azide Cycloaddition) in a one-pot reaction wi

COFERONS AND METHODS OF MAKING AND USING THEM

The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.

3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.

TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.